Amgen Milestones

2004

  • FDA approves Sensipar (cinacalcet HCl) for the treatment of secondary hyper-parathyroidism in chronic kidney disease patients on dialysis and for the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma
  • FDA approves Enbrel for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy
2003
  • FDA approves Enbrel for the treatment of ankylosing spondylitis and other expanded indications
2002
  • FDA approves Enbrel to treat the signs and symptoms of active arthritis in patients with psoriatic arthritis
  • FDA approves Neulasta to decrease the incidence of infection in patients with non-myeloid cancers receiving myelosuppressive chemotherapy
  • Amgen completes Immunex acquisition
  • FDA approves Aranesp for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies
  • FDA approves Amgen's Rhode Island manufacturing facility for Enbrel
2001
  • FDA approves Kineret to treat the signs and symptoms in patients with moderately to severely active rheumatoid arthritis whose disease has failed to respond to one or more disease-modifying medicines
  • Kevin W. Sharer named chairman
  • FDA approves Aranesp to treat anemia associated with chronic renal failure, including patients on dialysis and not on dialysis
2000
  • Kevin Sharer named CEO
  • Amgen acquires Kinetix Pharmaceuticals
1999
  • Gordon M. Binder retires
  • Amgen reaches sales of more than $3 billion
  • FDA approves Enbrel to treat patients with moderately to severely active polyarticular-course juvenile rheumatoid arthritis whose disease has failed to respond to prior disease-modifying medicines
1998
  • FDA approves Neupogen for use in support of treatment of acute myeloid leukemia
  • FDA approves Enbrel to treat patients with rheumatoid arthritis whose disease has failed to respond to prior disease-modifying medicines
1997
  • FDA approves Infergen for treating patients with Hepatitis C
1996
  • FDA approves Epogen for reduction of allogeneic blood transfusion in surgery patients
  • Amgen reaches sales of more than $2 billion
1995
  • FDA approves Neupogen for use in peripheral blood progenitor cell transplants
1994
  • FDA approves Neupogen for patients undergoing bone marrow transplantation and for patients with severe chronic neutropenia
  • Amgen receives U.S. Dept. of Commerce National Medal of Technology
  • Amgen completes acquisition of Synergen
1993
  • FDA approves Epogen for treatment of anemia in cancer patients on chemotherapy
1992
  • Kevin W. Sharer elected President and COO
  • Amgen reaches sales of more than $1 billion
  • Amgen added to the S&P 500
1991
  • FDA approves Neupogen to decrease the incidence of infection associated with chemotherapy-induced neutropenia in patients with non-myeloid cancers receiving myelosuppressive therapy
  • Amgen establishes the Amgen Foundation for charitable giving
  • Neupogen named "Product of the Year" by Fortune magazine
1990
  • George B. Rathmann retires
  • Gordon M. Binder elected Chairman of Amgen's Board of Directors
1989
  • Immunex clones TNF receptor, later patented and named Enbrel
  • Amgen receives first U.S. patent for recombinant G-CSF Neupogen
  • FDA approves Epogen for the treatment of anemia in patients with end-stage renal disease
  • Epogen named "Product of the Year" by Fortune magazine
  • Amgen added to the NASDAQ 100 Index
1988
  • Gordon M. Binder elected CEO
1987
  • Company changes name to Amgen Inc. and becomes a Delaware corporation
  • Amgen receives first patent on DNA used in producing Epogen
1986
  • George B. Rathmann elected chairman of Amgen's board of directors
1985
  • Larry M. Souza's team clones granulocyte colony-stimulating factor (G-CSF), later patented and named Neupogen
1983
  • Company changes name to Amgen
  • A team led by Fu-Kuen Lin clones erythropoietin, later patented and named Epogen
  • IPO of 2,350,000 shares at $18 per share results in $40 million raised; ticker symbol: AMGN
1981
  • Company changes name to Applied Molecular Genetics Inc.
1980
  • Venture capitalists Bill Bowes, Franklin "Pitch" Johnson, Sam Wohlsteadter and Raymond Baddour establish AMGen (Applied Molecular Genetics Inc.) as a California corporation on April 8
  • George B. Rathmann elected president and CEO
Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish